Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company has to approach the DCGI for approval to commence the trials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Company working on COVID vaccine INO 4800
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Subscribe To Our Newsletter & Stay Updated
